Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: TSE:COM
- CUSIP: N/A
- Web: www.cardiome.com/
- Market Cap: C$177.19 million
- Outstanding Shares: 31,927,000
- 50 Day Moving Avg: C$5.56
- 200 Day Moving Avg: C$4.60
- 52 Week Range: C$3.25 - C$7.15
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.16
- Annual Revenue: C$23.37 million
- Price / Sales: 7.58
- Book Value: C$0.88 per share
- Price / Book: 6.31
- EBIDTA: ($15,620,000.00)
- Net Margins: -121.81%
- Return on Equity: -81.68%
- Return on Assets: -40.03%
- Average Volume: 7,271 shs.
- Short Ratio: 7.15
Frequently Asked Questions for Cardiome Pharma Corp (TSE:COM)
What is Cardiome Pharma Corp's stock symbol?
Cardiome Pharma Corp trades on the Tornton Stock Exchange (TSX) under the ticker symbol "COM."
How were Cardiome Pharma Corp's earnings last quarter?
Cardiome Pharma Corp (TSE:COM) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.10. The company had revenue of $8.40 million for the quarter, compared to the consensus estimate of $7.37 million. Cardiome Pharma Corp had a negative net margin of 121.81% and a negative return on equity of 81.68%. View Cardiome Pharma Corp's Earnings History.
Who are some of Cardiome Pharma Corp's key competitors?
Some companies that are related to Cardiome Pharma Corp include Teranga Gold Corp (TGZ), MCAN Mortgage (MKP), BlackPearl Resources (PXX), Atlantic Power Corp (ATP), Denison Mines Corp (DML), Mainstreet Equity Corp. (MEQ), Information Services Corp (ISV), Firm Capital Mortgage Investment Corp (FC), Wesdome Gold Mines Ltd (WDO), Gdi Integrated Facility Services (GDI), Asanko Gold (AKG), Freshii (FRII), Acadian Timber Corp (ADN), Belo Sun Mining Corp (BSX), Absolute Software (ABT), CRH Medical Corp (CRH), Golden Star Resources (GSC) and Cona Resources Ltd (NBZ).
Who are Cardiome Pharma Corp's key executives?
Cardiome Pharma Corp's management team includes the folowing people:
- W. James O'Shea, Independent Chairman of the Board
- William L. Hunter M.D., President, Chief Executive Officer, Director
- Justin A. Renz, Chief Financial Officer
- Sheila M. Grant, Chief Operating Officer
- David D. McMasters J.D., Corporate General Counsel
- David C. Dean, Chief Business Development Officer
- Jennifer Archibald CPA, Chief Business Operations Officer
- Hugues Sachot, Chief Commercial Officer
- Richard M. Glickman LL.D., Lead Independent Director
- Mark H.N. Corrigan M.D., Independent Director
How do I buy Cardiome Pharma Corp stock?
Shares of Cardiome Pharma Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Cardiome Pharma Corp's stock price today?
MarketBeat Community Rating for Cardiome Pharma Corp (TSE COM)MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cardiome Pharma Corp stock can currently be purchased for approximately C$5.55.
Consensus Ratings for Cardiome Pharma Corp (TSE:COM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cardiome Pharma Corp (TSE:COM)
(Data available from 7/27/2015 forward)
|5/17/2017||HC Wainwright||Reiterated Rating||Buy|
|11/9/2016||Bloom Burton||Reiterated Rating||Buy|
Earnings History for Cardiome Pharma Corp (TSE:COM)Earnings History by Quarter for Cardiome Pharma Corp (TSE COM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/11/2014||($0.18)||($0.28)||$7.37 million||$8.40 million||View||N/A|
Earnings Estimates for Cardiome Pharma Corp (TSE:COM)
2017 EPS Consensus Estimate: ($0.68)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cardiome Pharma Corp (TSE:COM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cardiome Pharma Corp (TSE:COM)Insider Trades by Quarter for Cardiome Pharma Corp (TSE:COM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for Cardiome Pharma Corp (TSE:COM)
Latest Headlines for Cardiome Pharma Corp (TSE:COM)
Cardiome Pharma Corp (COM) Chart for Thursday, July, 27, 2017